Grassley Wants More Active FDA Oversight Of 510(k) Modification Decisions

Sen. Chuck Grassley, R-Iowa, is questioning why FDA does not play a more active role in determining when a change to a device requires a new 510(k)

More from Archive

More from Medtech Insight